The United States contributed to the Epidermolysis Bullo's highest prevalent cases, accounting for ~65% of the 7MM in 2023.

CLEVELAND, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the ...

GENEVA, SWITZERLAND / ACCESSWIRE / /RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the ...

The Company's BLA for pz-cel was previously accepted for Priority Review by the FDA for patients with RDEB. Abeona may be ...

The Food and Drug Administration (FDA) has accepted for review the resubmitted Biologics License Application (BLA) for prademagene zamikeracel for the treatment of recessive dystrophic epidermolysis ...

FDA accepts BLA resubmission of pz-cel in recessive dystrophic epidermolysis bullosa and sets PDUFA target action date of April 29, 2025 Company makes significant progress toward potential commerciali ...

Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa 11-Nov-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art.

Abeona Therapeutics (ABEO) announced that the U.S. Food and Drug Administration, FDA, has accepted for review Abeona’s resubmission of ...

Irish actor Colin Farrell recently finished the Dublin Marathon in 4:06:45, and he ran the last 2.5 miles while pushing his ...